Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated,advanced non-small cell lung cancer

作     者：Hideharu Kimura Tomoyuki Araya Taro Yoneda Hiroki Shirasaki Koji Kurokawa Tamami Sakai Hayato Koba Yuichi Tambo Shingo Nishikawa Takashi Sone Kazuo Kasahara 

作者机构：Respiratory MedicineKanazawa University HospitalTakara-machi 13-1KanazawaIshikawa 920-8641Japan Respiratory MedicineNational Hospital Organization Kanazawa Medical CenterKanazawaIshikawa 920-8650Japan Respiratory MedicineKomatsu Municipal HospitalKomatsuIshikawa 923-8560Japan Respiratory MedicineFukui-ken Saiseikai HospitalFukuiFukui 918-8503Japan Respiratory MedicineIshikawa Prefectural Central HospitalKanazawaIshikawa 920-8530Japan Internal MedicineKeiju Medical CenterNanaoIshikawa 926-8605Japan Regional Respiratory SymptomatologyKanazawa University Graduate School of Medical ScienceKanazawaIshikawa 920-8641Japan 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2019年第39卷第1期

页      面：665-669页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：nivolumab patients lung 

摘      要：Dear Editor,Nivolumab,an inhibitor of programmed cell death 1(PD-1),is an immune checkpoint inhibitor(ICI)that enhances T cell functions by preventing negative regulation of cancer immunity,and it has shown clinically significant efficacy and tolerability in various types of *** on the results of randomized phase III trials comparing nivolumab with docetaxel[1,2],nivolumab is now used in clinical practice for patients with previously treated advanced non-small cell lung cancer(NSCLC).Fur-thermore,the most recent Japan Lung Cancer Society guidelines include nivolumab monotherapy in the sys-temic treatment strategy for previously treated,locally advanced or metastatic NSCLC[3].However,ICIs induce characteristic immune-related adverse events(irAEs),which are not seen with conventional cytotoxic agents or molecular targeted *** can occur in any organ system,most typically the skin,lung,and gastrointesti-nal,hepatic,and endocrine systems.